NCT01300793 - Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

April 30, 2012

Conditions

Non-Hodgkin's LymphomaB-cell Lymphoma

Interventions

DRUG

Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide

Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 \& 11 q. 28 days.

Trial Locations (1)

94143

Unviersity of California Medical Center, San Francisco